SCLC
Oncology · 2010–2026
9decisions
5medicines
5carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| tarlatamab Treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy (second-line… | Mar 2026 | Not recommended | unclear |
| lurbinectedin First-line maintenance treatment of extensive-stage small cell lung cancer (ES-SCLC) in combination with atezolizumab for patients who have not progressed on… | Nov 2025 | Recommended with restriction | unclear |
| atezolizumab Subcutaneous injection formulation for multiple cancer indications including locally advanced or metastatic NSCLC, stage IV metastatic NSCLC, extensive-stage… | Mar 2024 | Recommended with restriction | input received Rare Cancers Australia · Lung Foundation Australia |
| topotecan Treatment of metastatic carcinoma of the ovary after failure of first-line or subsequent therapy; small cell lung carcinoma after failure of first-line… | Jul 2020 | Recommended with restriction | input received Lung Foundation Australia |
| durvalumab First-line treatment of extensive stage small cell lung cancer (ES-SCLC) in previously untreated patients with WHO performance status 0 or 1, in combination… | Nov 2020 | Recommended with restriction | input received Lung Foundation Australia · Rare Cancers Australia · Medical Oncology Group |
| atezolizumab First-line treatment of previously untreated patients with extensive-stage small cell lung cancer (ES-SCLC) with Eastern Cooperative Oncology Group (ECOG)… | Jul 2019 | Not recommended | input received |
| atezolizumab First-line treatment of previously untreated patients with extensive-stage small cell lung cancer (ES-SCLC) with ECOG performance status 0-1, in combination… | Nov 2019 | Recommended with restriction | input received Medical Oncology Group |
| topotecan treatment of relapsed or refractory small cell lung cancer (SCLC) where intravenous (IV) therapy is inappropriate | Jul 2010 | Not recommended | no section in document |
| topotecan Treatment of relapsed or refractory small cell lung cancer (SCLC) where intravenous therapy is inappropriate. | Jul 2010 | Not recommended | no section in document |
Who spoke
Lung Foundation Australia · Medical Oncology Group · Rare Cancers Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 5 of 7 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.